Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY20 results · Jan–Mar 2020
Gufic Biosciences reported revenue from operations of ₹81.59 crore (down 10.9% from Q4 FY19) and net profit of ₹4.72 crore (down 21.5% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 81.59 | 91.55 | −10.9% | 97.74 | −16.5% |
| Other income | 1.13 | 3.29 | −65.7% | 3.06 | −63.2% |
| Total income | 82.72 | 94.83 | −12.8% | 100.80 | −17.9% |
| Profit before tax | 6.07 | 10.75 | −43.5% | 9.42 | −35.5% |
| Net profit for the period | 4.72 | 6.01 | −21.5% | 7.02 | −32.7% |
| EPS, basic (₹) | 0.61 | 0.77 | −20.8% | 0.90 | −32.2% |
| Net margin (%) | 5.8 | 6.6 | 7.2 |
Standalone
- Filed with BSE
- 06 Aug 2020, 17:11 IST
- Board meeting
- 31 Jul 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE